Novo-Nordisk A/S

Recent news

• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45
  Market Newswire · 6/22
• Novo-Nordisk A/S (NVO.US) has submitted a marketing application in China for Wegovy tablets for long-term weight management.
  Zhitong Finance · 8/27
• Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47
  Market Newswire · 6/3
• TD Cowen Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $42
  Market Newswire · 3/10
• Analysts' Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)
  TipRanks · 8/3
• Berenberg Bank Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $47
  Market Newswire · 3/12
• Novo-Nordisk A/S (NVO.US) Q2 earnings beat expectations and full-year guidance was raised, yet underlying concerns persist! Weak sales of oral Wegovy cast a shadow over its path back to growth.
  Zhitong Finance · 8/5
• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47
  Market Newswire · 8/6
• Eli Lilly and Co (LLY.US) and Novo-Nordisk A/S (NVO.US) win GLP-1 antitrust lawsuit as U.S. court dismisses allegations by rival pharmacy
  Zhitong Finance · 8/7
• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
  Market Newswire · 8/18

Headlines are aggregated automatically and are not independently verified or edited by our team.